| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | lapatinib | UHNBreast | pan-cancer | AAC | -0.36 | 0.2 |
| mRNA | Erlotinib | UHNBreast | pan-cancer | AAC | -0.31 | 0.3 |
| mRNA | AZD6244 | UHNBreast | pan-cancer | AAC | -0.26 | 0.4 |
| mRNA | myriocin | CTRPv2 | pan-cancer | AAC | -0.18 | 0.04 |
| mRNA | Vandetanib | CCLE | pan-cancer | AAC | -0.17 | 0.0007 |
| mRNA | lapatinib | CCLE | pan-cancer | AAC | -0.16 | 0.0006 |
| mRNA | lapatinib | gCSI | pan-cancer | AAC | -0.16 | 0.006 |
| mRNA | SR-II-138A | CTRPv2 | pan-cancer | AAC | -0.16 | 3e-06 |
| mRNA | BRD-K01737880 | CTRPv2 | pan-cancer | AAC | -0.15 | 0.2 |
| mRNA | VX-680 | CTRPv2 | pan-cancer | AAC | -0.14 | 0.2 |